Outcomes of lenvatinib therapy in poorly differentiated thyroid carcinoma

Detalhes bibliográficos
Autor(a) principal: Roque, João
Data de Publicação: 2023
Outros Autores: Silva, Tiago Nunes, Regala, Catarina, Rodrigues, Ricardo, Leite, Valeriano
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
Texto Completo: http://hdl.handle.net/10362/153051
Resumo: Funding Information: Ricardo Rodrigues was granted with a PhD scholarship by iNOVA4Health Research Unit (UIDP/04462/2020; UI/BD/154256/2022). The remaining authors did not receive any specific grant from funding agencies in the public, commercial, or non-for-profit sectors. Publisher Copyright: © 2023 the author(s) Published by Bioscientifica Ltd.
id RCAP_c6c1cd5dc03a70252708c8c3bd3f9570
oai_identifier_str oai:run.unl.pt:10362/153051
network_acronym_str RCAP
network_name_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository_id_str 7160
spelling Outcomes of lenvatinib therapy in poorly differentiated thyroid carcinomaeffectivenesslenvatiniboutcomespoorly differentiated thyroid carcinomaEndocrinology, Diabetes and MetabolismSDG 3 - Good Health and Well-beingFunding Information: Ricardo Rodrigues was granted with a PhD scholarship by iNOVA4Health Research Unit (UIDP/04462/2020; UI/BD/154256/2022). The remaining authors did not receive any specific grant from funding agencies in the public, commercial, or non-for-profit sectors. Publisher Copyright: © 2023 the author(s) Published by Bioscientifica Ltd.Background and objective: Lenvatinib showed promising results in a subgroup of patients with poorly differentiated thyroid carcinoma (PDTC) in the SELECT trial. Our aim was to report the effectiveness and tolerability of lenvatinib in our series of PDTC patients. Methods: Medical records of eight consecutive patients with PDTC treated with lenvatinib in a single center between January 2019 and October 2022 were retrospectively reviewed. Inclusion criteria were PDTC diagnosis based on Turin criteria and evidence of disease progression in the previous 6 months. Results: Eight PDTC patients received an average dose of lenvatinib of 18.1 mg for a median duration of treatment of 10.3 months. The baseline Eastern Cooperative Oncology Group performance status was ≥2 in 50% of patients. Two patients had unresectable primary tumor. Seven patients showed extrathyroidal disease, particularly mediastinal lymph nodes (85.7%), lung (71.4%), and bone (71.4%). The disease control rate was 100%, with partial response and stable disease in 12.5 and 87.5%, respectively. The median time to best overall response was 3 months, and the median duration of response was 7.5 months. Median progression-free survival was 12 months and median overall survival was not reached. At 6, 12, and 18 months, overall survival was 87.5, 71.4, and 57.1%, respectively. All patients experienced drug-related adverse effects (AEs). Four (50%) had dose reductions and two (25%) had temporary treatment interruptions. Lenvatinib was stopped in two patients due to grade ≥3 AEs. Conclusion: Lenvatinib is an effective treatment for real-world PDTC patients. Adequate management of comorbidities and AEs increases treatment tolerability and minimizes dose reductions.NOVA Medical School|Faculdade de Ciências Médicas (NMS|FCM)RUNRoque, JoãoSilva, Tiago NunesRegala, CatarinaRodrigues, RicardoLeite, Valeriano2023-05-22T22:18:21Z2023-042023-04-01T00:00:00Zinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleapplication/pdfhttp://hdl.handle.net/10362/153051eng2235-0640PURE: 60956091https://doi.org/10.1530/ETJ-23-0003info:eu-repo/semantics/openAccessreponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãoinstacron:RCAAP2024-03-11T05:35:35Zoai:run.unl.pt:10362/153051Portal AgregadorONGhttps://www.rcaap.pt/oai/openaireopendoar:71602024-03-20T03:55:09.139613Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãofalse
dc.title.none.fl_str_mv Outcomes of lenvatinib therapy in poorly differentiated thyroid carcinoma
title Outcomes of lenvatinib therapy in poorly differentiated thyroid carcinoma
spellingShingle Outcomes of lenvatinib therapy in poorly differentiated thyroid carcinoma
Roque, João
effectiveness
lenvatinib
outcomes
poorly differentiated thyroid carcinoma
Endocrinology, Diabetes and Metabolism
SDG 3 - Good Health and Well-being
title_short Outcomes of lenvatinib therapy in poorly differentiated thyroid carcinoma
title_full Outcomes of lenvatinib therapy in poorly differentiated thyroid carcinoma
title_fullStr Outcomes of lenvatinib therapy in poorly differentiated thyroid carcinoma
title_full_unstemmed Outcomes of lenvatinib therapy in poorly differentiated thyroid carcinoma
title_sort Outcomes of lenvatinib therapy in poorly differentiated thyroid carcinoma
author Roque, João
author_facet Roque, João
Silva, Tiago Nunes
Regala, Catarina
Rodrigues, Ricardo
Leite, Valeriano
author_role author
author2 Silva, Tiago Nunes
Regala, Catarina
Rodrigues, Ricardo
Leite, Valeriano
author2_role author
author
author
author
dc.contributor.none.fl_str_mv NOVA Medical School|Faculdade de Ciências Médicas (NMS|FCM)
RUN
dc.contributor.author.fl_str_mv Roque, João
Silva, Tiago Nunes
Regala, Catarina
Rodrigues, Ricardo
Leite, Valeriano
dc.subject.por.fl_str_mv effectiveness
lenvatinib
outcomes
poorly differentiated thyroid carcinoma
Endocrinology, Diabetes and Metabolism
SDG 3 - Good Health and Well-being
topic effectiveness
lenvatinib
outcomes
poorly differentiated thyroid carcinoma
Endocrinology, Diabetes and Metabolism
SDG 3 - Good Health and Well-being
description Funding Information: Ricardo Rodrigues was granted with a PhD scholarship by iNOVA4Health Research Unit (UIDP/04462/2020; UI/BD/154256/2022). The remaining authors did not receive any specific grant from funding agencies in the public, commercial, or non-for-profit sectors. Publisher Copyright: © 2023 the author(s) Published by Bioscientifica Ltd.
publishDate 2023
dc.date.none.fl_str_mv 2023-05-22T22:18:21Z
2023-04
2023-04-01T00:00:00Z
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://hdl.handle.net/10362/153051
url http://hdl.handle.net/10362/153051
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv 2235-0640
PURE: 60956091
https://doi.org/10.1530/ETJ-23-0003
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.source.none.fl_str_mv reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron:RCAAP
instname_str Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron_str RCAAP
institution RCAAP
reponame_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
collection Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository.name.fl_str_mv Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
repository.mail.fl_str_mv
_version_ 1799138139403452416

Registros relacionados